ABT-199 (Venetoclax), a BH3-mimetic Bcl-2 inhibitor, does not cause Ca^{2+}-signalling dysregulation or toxicity in pancreatic acinar cells

**Correspondence** Geert Bultynck and Tim Vervliet, Laboratory of Molecular and Cellular Signaling, Department of Cellular and Molecular Medicine, KU Leuven, Campus Gasthuisberg, O&N I Herestraat 49 – bus 802, Leuven B-3000, Belgium. E-mail: geert.bultynck@kuleuven.be; tim.vervliet@kuleuven.be; Pawel Ferdek, Department of Cell Biology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, Krakow 30-387, Poland. E-mail: p.e.ferdek@gmail.com

**Received** 1 March 2018; **Revised** 21 August 2018; **Accepted** 13 September 2018

Monika A Jakubowska\(^1,2\), Martijn Kerkhofs\(^3\), Claudio Martines\(^4\), Dimitar G Efremov\(^4\), Julia V Gerasimenko\(^1\), Oleg V Gerasimenko\(^1\), Ole H Petersen\(^1\), Geert Bultynck\(^3\), Tim Vervliet\(^3*\) and Pawel E Ferdek\(^1,5*\)

\(^1\)Medical Research Council Group, School of Biosciences, Cardiff University, Cardiff, UK, \(^2\)International Associated Laboratory (LIA), Malopolska Centre of Biotechnology, Jagiellonian University, Krakow, Poland, \(^3\)Laboratory of Molecular and Cellular Signaling, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium, \(^4\)Molecular Hematology Unit, International Centre for Genetic Engineering and Biotechnology, Trieste, Italy, and \(^5\)Department of Cell Biology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland

*These authors contributed equally as senior authors.

**BACKGROUND AND PURPOSE**

Many cancer cells depend on anti-apoptotic B-cell lymphoma 2 (Bcl-2) proteins for their survival. Bcl-2 antagonism through Bcl-2 homology 3 (BH3) mimetics has emerged as a novel anti-cancer therapy. ABT-199 (Venetoclax), a recently developed BH3 mimic that selectively inhibits Bcl-2, was introduced into the clinic for treatment of relapsed chronic lymphocytic leukaemia. Early generations of Bcl-2 inhibitors evoked sustained Ca^{2+} responses in pancreatic acinar cells (PACs) inducing cell death. Therefore, BH3 mimetics could potentially be toxic for the pancreas when used to treat cancer. Although ABT-199 was shown to kill Bcl-2-dependent cancer cells without affecting intracellular Ca^{2+} signalling, its effects on PACs have not yet been determined. Hence, it is essential and timely to assess whether this recently approved anti-leukaemic drug might potentially have pancreatotoxic effects.

**EXPERIMENTAL APPROACH**

Single-cell Ca^{2+} measurements and cell death analysis were performed on isolated mouse PACs.

**KEY RESULTS**

Inhibition of Bcl-2 via ABT-199 did not elicit intracellular Ca^{2+} signalling on its own or potentiate Ca^{2+} signalling induced by physiological/pathophysiological stimuli in PACs. Although ABT-199 did not affect cell death in PACs, under conditions that killed ABT-199-sensitive cancer cells, cytosolic Ca^{2+} extrusion was slightly enhanced in the presence of ABT-199. In contrast, inhibition of Bcl-xL potentiated pathophysiological Ca^{2+} responses in PACs, without exacerbating cell death.

**CONCLUSION AND IMPLICATIONS**

Our results demonstrate that apart from having a modest effect on cytosolic Ca^{2+} extrusion, ABT-199 does not substantially alter intracellular Ca^{2+} homeostasis in normal PACs and should be safe for the pancreas during cancer treatment.

**LINKED ARTICLES**

This article is part of a themed section on Mitochondrial Pharmacology: Featured Mechanisms and Approaches for Therapy Translation. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.22/issuetoc

**Abbreviations**

\([Ca^{2+}]_i\), intracellular cytosolic Ca^{2+} concentration; Bak, Bcl-2 homologous antagonist killer; Bax, Bcl-2-associated X protein; Bcl-2, B-cell lymphoma 2; Bcl-w, Bcl-2-like protein 2; Bcl-xL, Bcl-extra large; BH, Bcl-2 homology; Bim, Bcl-2-like protein 11; CCK, cholecystokinin; CCL, chronic lymphocytic leukaemia; DLBCL, diffuse large B-cell lymphoma; IP\(_3\)R, inositol 1,4,5-trisphosphate receptor; PAC, pancreatic acinar cell; PMCA, plasma membrane Ca^{2+} ATPase; RyR, ryanodine receptor; SERCA, sarco/endoplasmic reticulum Ca^{2+} ATPase; Tg, thapsigargin; TLC-S, tauroliothioleic acid 3-sulfate
**Introduction**

Impaired regulation of apoptosis is crucial to the process of carcinogenesis enabling cancer cells to evade cell death signals triggered by oncogenic stress and acquiring metastatic properties by accumulation of secondary genetic mutations (Adams and Cory, 2007; Hanahan and Weinberg, 2011). In cancer cells, this is achieved by altered expression levels of either the pro- or anti-apoptotic B-cell lymphoma 2 (Bcl-2) family members, predominantly located at the mitochondrial membranes (Davids and Letai, 2012). Pro-apoptotic Bcl-2-associated X protein (Bax) and Bcl-2 homologous antagonist killer (Bak) are critical in the initiation of mitochondrial outer membrane permeabilization, the point of no return for apoptosis induction, whereas the anti-apoptotic Bcl-2 members such as Bcl-2, Bcl-extra large (Bcl-XL) or Bcl-2-like protein 2 (Bcl-w) counteract this process (Chipuk et al., 2008). Bcl-2-dependent cancers are often ‘primed for death’, a term used to describe the necessity of expressing high levels of the anti-apoptotic Bcl-2 proteins in order to actively sequester and inhibit the pro-apoptotic family members, particularly Bax and the activator Bcl-2 homology 3 (BH3)-only protein Bcl-2-like protein 11 (Bim) (Akl et al., 2014). Therefore, pharmacological disruption of the interaction between the anti- and pro-apoptotic Bcl-2 family members has the potential to activate Bax/Bak, and restore the programmed cell death (Wang et al., 2000; Chipuk et al., 2008). This spurred the development of Bcl-2 antagonists that target the hydrophobic cleft of the anti-apoptotic Bcl-2 proteins displacing Bax/Bak and Bim from Bcl-2. A very successful strategy has been the development of so-called ‘BH3 mimetic’ molecules that structurally resemble the BH3 domain of sensitizer BH3-only proteins like Bad (Bcl-2-associated death promoter), thereby inhibiting Bcl-2 without directly activating Bax/Bak (Oltersdorf et al., 2005).

The early generation of BH3 mimetics, such as HA14-1 and BH3I-2, despite being able to disrupt the interaction between the pro- and anti-apoptotic proteins to initiate apoptosis (Wang et al., 2000; Degterev et al., 2001), had serious limitations that prevented their translation into the clinic. Some of these limitations have been linked to their adverse impact on the Ca^{2+} signalling machinery in non-tumoural cells that is essential for intracellular Ca^{2+} homeostasis, cell function and survival (Vervloesem et al., 2018). For instance, HA14-1 also inhibits the Ca^{2+}-pump activity of the sarco/endoplasmic reticulum Ca^{2+}-ATPase (SERCA), provoking cell death in part by depleting the ER Ca^{2+}-store (Hermanson et al., 2009; Akl et al., 2013). Moreover, both HA14-1 and BH3I-2 were found to have pancreatotoxic effects (Gerasimenko et al., 2010; Ferdek et al., 2017). These effects were mediated directly by pathological Ca^{2+} responses in pancreatic acinar cells (PACs), the secretory epithelium that produces and releases digestive enzymes in the pancreas (Gerasimenko et al., 2010). It is well established that excessive Ca^{2+} signals underlie the pathogenesis of acute pancreatitis, a severe human disease (Gerasimenko et al., 2018). Moreover, dysregulation of Ca^{2+} homeostasis has also been implicated in the development of acute pancreatitis provoked by the anti-leukaemic drug L-asparaginase, which is used to treat childhood acute lymphoblastic leukaemia (Peng et al., 2018; Vervliet et al., 2018). In such cases, the anti-cancer therapy must be ceased. At the mechanistic level, an excessive intracellular cytosolic Ca^{2+} concentration ([Ca^{2+}]_{i}) together with the depletion of intracellular Ca^{2+} stores in the ER and acidic pools, including zymogen granules, triggers premature protease activation in situ in PACs leading to autodigestion of the tissue (Petersen et al., 2011).

Nevertheless, the development of BH3 mimetics continued, resulting in ABT-737 and its orally available successor ABT-263 (navitoclax), as selective on-target inhibitors of Bcl-2, Bcl-xL and Bcl-w that are able to induce cancer cell death (Oltersdorf et al., 2005; Del Gaizo Moore et al., 2008). Although these two pharmacological agents were shown to be effective at killing several Bcl-2-dependent cancer types (Oltersdorf et al., 2005; Tse et al., 2008), they were also found to induce thrombocytopenia and deregulate Ca^{2+} homeostasis in platelets, effects attributed to Bcl-xl inhibition (Schoenwaelder et al., 2011; Vogler et al., 2011). Recently, ABT-199 (venetoclax) has been developed (Souver et al., 2013). This orally bioavailable selective inhibitor of Bcl-2 was shown to cause cell death in chronic lymphocytic leukaemia (CLL) cells with an EC_{50} < 10 nM (Souers et al., 2013). In 2016, ABT-199 became the first ever clinically approved small molecule drug targeting a protein–protein interaction, and since then it has been used in the clinic as a therapy for relapsed CLL (Green, 2016). This drug is attracting a lot of interest and is currently undergoing further clinical trials, often in combination with other chemotherapeutic agents (Ferdek and Jakubowska, 2017).

Given that several of the early BH3 mimetics have been shown to alter intracellular Ca^{2+} signalling, particularly in the pancreas (Gerasimenko et al., 2010; Ferdek et al., 2017), it became essential and timely to determine whether or not the recently approved anti-leukaemic drug ABT-199 and other inhibitors such as selective Bcl-xL antagonist A-1155463 and Bcl-2/Bcl-xL inhibitor ABT-737 show effects that might potentially be pancreatotoxic. Although ABT-199 was shown not to dysregulate intracellular Ca^{2+} signalling upon acute application in the Bcl-2-dependent diffuse large Bcl (DLBCL) cell lines (Vervloessem et al., 2017b, 2018), data on healthy primary cells are very limited. It is also unclear whether prolonged exposure to ABT-199 could influence intracellular Ca^{2+} signalling in normal PACs. What is more, in PACs, physiological enzyme secretion is controlled by [Ca^{2+}]_{i}, oscillations triggered by ACh and cholecystokinin (CCK) (Petersen and Tepikin, 2008). Therefore, it is also important to assess whether these physiological Ca^{2+} signals are affected by ABT-199. Furthermore, inducers of pancreatitis, such as certain bile acids, initiate pancreatic pathology via abnormal Ca^{2+} responses (Gerasimenko et al., 2006; Ferdek et al., 2016). However, potential synergistic effects between those inducers and ABT-199, which may lead to aggravation of the disease, have not yet been addressed. ABT-199 has already been introduced successfully into the clinic as an anti-leukaemic agent, and its potential therapeutic applications are likely to increase in due course. Since acute pancreatitis is a side effect of some (5–10% of cases) existing therapies for acute lymphoblastic leukaemia in children (Kearney et al., 2009; Raja et al., 2014) and Ca^{2+} signals have been implicated in this process (Peng et al., 2016), it has become particularly relevant to assess the impact of ABT-199 (along with the selective Bcl-xL inhibitor A-1155463 and
the Bcl-2/Bcl-xL inhibitor ABT-737) on intracellular Ca²⁺ homoeostasis and dynamics in healthy PACs.

Methods

Animals: Housing, husbandry and experimental procedures

Experimental animals (6-week-old male C57BL6/J mice, 23 ± 3 g) were purchased from Charles River UK and then housed in the Cardiff University or the Jagiellonian University institutional animal units (12 h light cycle) and maintained on a standard rodent chow diet with free access to water. Up to five mice were kept per cage with aspen wood bedding material and an enriched environment (cardboard tunnel, nesting material, wooden gnawing sticks, etc.). All procedures involving animals were performed in accordance with the UK Home Office or the Polish Ministry of Science and Higher Education regulations. The mice were humanely killed by cervical dislocation according to Schedule 1 of Animals (Scientific Procedures) Act 1986. The pancreatic tissue was removed for further experimental procedures. In order to reduce the number of animals needed for the experiments (in line with the 3Rs), cells isolated from one animal were used by two researchers simultaneously.

Isolation of PACs

PAC isolation was performed as described previously (Ferdek et al., 2017). The isolation and the experimental work was carried out in NaHEPES buffer. Unless otherwise stated, NaHEPES was supplemented with 1 mM Ca²⁺. Immediately after dissection, the pancreatic tissue was washed twice in NaHEPES, treated with collagenase (200 U·mL⁻¹, in NaHEPES) and then enzymatically digested in the collagenase solution at 37°C for 15 min. After digestion, the pancreas was broken down by pipetting, suspended in NaHEPES, spun (1 min, 0.2 x g), resuspended in NaHEPES and spun again. Finally, isolated cells were suspended in NaHEPES and loaded with a Ca²⁺-sensitive dye, Fluo-4, as described below.

Cytosolic Ca²⁺ measurements

Isolated PACs were loaded with 5 μM Fluo-4 AM [30 min, at room temperature (RT)]. After the incubation, the cells were resuspended in fresh NaHEPES and used for experiments (RT) in a flow chamber perfused with NaHEPES-based extracellular solution. Experiments were performed using the following equipment: (i) Zeiss LSM 880 confocal microscope (x63 oil objective) at the Jagiellonian University; and (ii) Leica TCS SPE confocal microscope (x63 oil objective) or Leica TCS SP5 II two-photon confocal microscope (x63 water objective) at Cardiff University. Excitation was set to 488 nm and emission to 500–600 nm. Static images were taken at 512 x 512 pixel resolution, and a series of images were recorded at 256 x 256 pixel resolution; two consecutive frames were averaged, and time resolution was one image per 2 s. Fluorescence signals were plotted as F/F₀, where F₀ was an averaged signal from the first 10 baseline images.

Cell death assay in PACs

Cell death assay was performed using an Annexin V-FITC/PI apoptosis detection kit. PACs were isolated as described above, spun down and then suspended in 3 mL of fresh NaHEPES. The cells were divided equally into the experimental groups (final volume of NaHEPES: 2 mL) and kept until further treatment (4°C). Then 1 mL of the buffer was removed, and the cells were treated with 1 mL of 2x concentrated incubation buffer containing menadione or TLC-S, and the vehicle (2 or 4 h, RT); the isolation quality control group was incubated with NaHEPES only. Also, in some treatment groups, the incubation buffer at this stage was supplemented with the BH3 mimetics: ABT-199, A-1155463, ABT-199 together with A-1155463, or ABT-737. The final concentrations were as follows: menadione 60 μM and TLC-S 200 μM; and the BH3 mimetics: 1 μM ABT-199, 1 μM A-1155463, 1 μM ABT-199 together with 1 μM A-1155463, or 10 μM ABT-737. Owing to the limited amount of mouse PACs obtained in a single isolation procedure, all experimental groups but one were equal by design. For the cell death assay, the cells isolated from 16 pancreata were either treated with NaHEPES (the isolation quality control, N = 16) or randomized to the experimental groups with five independent pancreata per group (N = 5). Since the NaHEPES-treated sample served as the control for each individual pancreas isolation (16 in total) subsequently used in the cell death experiments, N = 16 for this condition. Fifteen minutes before the end of the incubation, Annexin V-FITC and PI were added to the samples. The cells were visualized with a TCS SP5 II two-photon confocal microscope (Leica) with a 63 x 1.2 NA water objective, and fluorescence/transmitted light images were taken. Annexin-V-FITC (excitation: 488 nm, emission: 510–555 nm) specifically stains apoptotic cells, whereas PI (excitation: 535 nm, emission: 585–650 nm) was used for detection of necrotic cells; the cells stained with both fluorescent dyes were classified as secondary necrosis. Fifteen pictures of independent cell clusters were taken at 512 x 512 pixel resolution. The percentage of live, apoptotic, secondary necrotic and necrotic cells were counted in each treatment group by one researcher in a blinded fashion (encoding the group labels).

Cell death assay in B-cell lymphoma lines and CLL patient samples

DLBCL cell lines were seeded at 250 000 cells·mL⁻¹ 24 h before treatment. Cells were harvested at 2, 4 and 6 h after 1 μM ABT-199 or vehicle treatment and stained with Alexa Fluor™ 488 Annexin V/7-AAD. Flow cytometry was used for data acquisition (Attune; Thermo Fisher Scientific) whereby viable cells were identified as being Annexin V/7-AAD negative. The analysis was performed using the FlowJo software.

Blood samples were collected from patients with CLL according to the principles established by the International Conference on Harmonization Guidelines on Good Clinical Practice. An informed consent was obtained from all patients and approval for the study was obtained from the ethical committee of the Università Cattolica del Sacro Cuore, Fondazione Policlinico A. Gemelli, Rome, Italy (protocol number 14563/15). The collection and analysis of CLL patient samples were performed as reported in Bojarczuk et al.
(2016). Briefly, mononuclear cells were isolated from peripheral blood samples by Ficoll gradient centrifugation. The proportion of CD5+CD19+ CLL cells was determined by flow cytometry; samples containing >85% CLL cells were used for the subsequent experiments. CLL cells were cultured at a cell density of 1 x 10⁷/mL in RPMI 1640 supplemented with 10% heat-inactivated FBS, 100 U/mL penicillin, 0.1 mg/mL streptomycin, 2 mM l-glutamine and 1 mM sodium pyruvate (Invitrogen) and treated for 2, 4 or 6 h with ABT-199 (1 μM) or vehicle. The percentage of apoptotic cells was determined by staining with PI and annexin-A5-FITC conjugate (Nexins Research) and analysis on an FACS Calibur flow cytometer with CellQuest Pro version 5.2.1 software (BD Biosciences).

Comparison of Ca²⁺ extrusion

In order to empty the ER Ca²⁺ stores, PACs were treated with 2 μM thapsigargin (Tg) for 10 min in the absence of extracellular Ca²⁺. Then the extracellular Ca²⁺ concentration was increased to 10 mM, which induced Ca²⁺ influx to the cytosol. Once a [Ca²⁺]ᵢ plateau was achieved, removal of extracellular Ca²⁺ unmasked the process of Ca²⁺ extrusion across the plasma membrane. This phase of the response was further analysed and compared between control and ABT-199 pretreated PACs. First, for every recorded [Ca²⁺]ᵢ trace, the time values corresponding to Fmax and 0.5 Fmax were calculated as the difference between t(Fₘᵡₓ) and t(Fₘᵡₓ) respectively. The 0.5 Fmax tₘᵡₓ values obtained for control and ABT-199-treated cells were then averaged and presented as dot charts ±SEM. Student’s post hoc test (whenever relevant) was performed if values of the F-test (used to assess the equalities of the means of a given set of normally distributed populations, all having the same SD) achieved the necessary level of statistical significance (P < 0.05).

Materials

The main reagents for cell isolation and imaging included: Annexin V-FITC/propidium iodide (PI) apoptosis detection kit, Fluo-4 AM (Thermo Fisher Scientific, Loughborough, UK); collagenase (Worthington, Lakewood, USA); ACh, CCK, inorganic salts, menadione, tauroliotholic acid 3-sulfate (TLC-S) (Sigma-Aldrich, Dorset, UK); and the BH3 mimetics: the Bcl-2 inhibitor ABT-199 (Active Biochem, Bonn, Germany), the Bcl-xl inhibitor A-1155463 (Selleckchem, Cambridgeshire, UK) and the non-selective Bcl-2, Bcl-xl and Bcl-w inhibitor ABT-737 (Santa Cruz Biotechnology, Heidelberg, Germany). NaHEPES buffer was prepared as follows (mM): NaCl 140, KCl 4.7, HEPES 10, MgCl₂ 2, μM penicillin, 1 μM streptomycin, 2 mM L-glutamine and 1 mM sodium pyruvate (Invitrogen) and treated for 2, 4 or 6 h with ABT-199 (1 μM) or vehicle. The percentage of apoptotic cells was determined by staining with PI and annexin-A5-FITC conjugate (Nexins Research) and analysis on an FACS Calibur flow cytometer with CellQuest Pro version 5.2.1 software (BD Biosciences).

Nomenclature of targets and ligands

Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018), and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017a,b,c,d).

Results

Selective inhibition of only one Bcl-2 family member by BH3 mimetics does not induce noxious Ca²⁺ responses

In order to compare the effects of acute inhibition of different Bcl-2-family members on Ca²⁺ homeostasis in PACs, several BH3 mimetics were tested (Figure 1). First, 10 μM ABT-737 was used to target the hydrophobic clefts of a wide range of Bcl-2 proteins: Bcl-2, Bcl-xl and Bcl-w (Figure 1A). Further pharmacological inhibition of two anti-apoptotic Bcl-2 family members, Bcl-2 and Bcl-xl, was achieved by the combination of two selective inhibitors at 1:1 ratio, 1 μM ABT-199 and 1 μM A-1155463 (Figure 1B). These selective inhibitors were then tested individually (Figure 1C, D). Given the higher affinity of ABT-199 and A-1155463 for the respective hydrophobic clefts of Bcl-2 and Bcl-xl, compared to ABT-737 (Konopleva et al., 2006; Souers et al., 2013; Tao et al., 2014), these two inhibitors were used at lower concentrations (1 μM vs. 10 μM). Intracellular Ca²⁺ signals were recorded in PACs loaded with Ca²⁺-sensitive fluorescent probe Fluo-4. After the baseline signal had been recorded for 200 s, the cells were treated with the indicated BH3 mimetics for 600 s. Finally, ACh at supramaximal concentration (10 μM) was used as a positive control for ER Ca²⁺-store loading.
Selective pharmacological inhibition of single anti-apoptotic Bcl-2 family members does not induce substantial Ca\textsuperscript{2+} responses in mouse PACs. ACh at supramaximal concentration (10 μM) triggers Ca\textsuperscript{2+} release from the ER and thus can be used to identify responding/live cells. Only PACs that responded to ACh were included in the analysis of these experiments. Green insets illustrate which Bcl-2 family proteins are targeted by the used inhibitors in each figure panel. N, number of independent repeats in the experiments; n, number of independent regions of interest in the experiment (see the text for details). (A) Sample traces (N = 7, n = 80) show three patterns of [Ca\textsuperscript{2+}] responses recorded in PACs upon acute application of 10 μM ABT-737, an inhibitor of Bcl-2 and Bcl-xL (as indicated in the figure); 46% of cells did not show any Ca\textsuperscript{2+} response (light grey), 34% of cells responded with one or more Ca\textsuperscript{2+} transients (dark grey), and 20% of cells developed an increased cytosolic Ca\textsuperscript{2+} plateau (black). (B) Sample traces (N = 6, n = 46) show three patterns of [Ca\textsuperscript{2+}] responses recorded in PACs upon acute application of 1 μM ABT-199 (selective Bcl-2 inhibitor) together with 1 μM A-1155463 (selective Bcl-xL inhibitor); 52% of cells did not show any Ca\textsuperscript{2+} response (light grey), 22% of cells responded with one or more Ca\textsuperscript{2+} transients (dark grey), and 26% of cells developed an increased cytosolic Ca\textsuperscript{2+} plateau (black). (C) Sample traces (N = 6, n = 41) show two patterns of [Ca\textsuperscript{2+}] responses recorded in PACs upon acute treatment with 1 μM A-1155463. In the majority of cells (76%), A-1155463 did not cause any Ca\textsuperscript{2+} response (light grey), whereas in approximately 24% of cells, single Ca\textsuperscript{2+} transients were recorded (dark grey). (D) Sample trace (N = 5, n = 52) shows lack of Ca\textsuperscript{2+} response to 1 μM ABT-199 in PACs (light grey). (E) Summary of [Ca\textsuperscript{2+}] response patterns in PACs to different inhibitors of Bcl-2 family members, colour coding as above. The selective pharmacological Bcl-2 inhibitor ABT-199 does not have a major effect on intracellular Ca\textsuperscript{2+} in acinar cells.
elicit any Ca\textsuperscript{2+} signals in PACs (light grey; Figure 1D). Even when ABT-199 was applied at a high dose (10 μM), the vast majority of cells (89%) did not develop Ca\textsuperscript{2+} responses and the remaining 11% of cells responded only with minor oscillations (not shown). Circular diagrams summarizing Ca\textsuperscript{2+} response patterns in PACs to different inhibitors of Bcl-2 family members are shown in Figure 1E (colour coding corresponds with the traces). Taken together, these data suggest that selective inhibition of one Bcl-2 family member does not induce substantial increases in intracellular Ca\textsuperscript{2+} (Figure 1C–E). In contrast, when more than one Bcl-2 family protein is targeted by a BH3 mimetic, the intracellular Ca\textsuperscript{2+} homeostasis is influenced to a much greater extent (Figure 1A, B, E).

**ABT-199, a selective inhibitor of Bcl-2, does not alter physiological Ca\textsuperscript{2+} responses in PACs**

ABT-199 has recently been approved by the US Food and Drug Administration as an anti-leukaemic agent. Therefore, identification of its potential side effects prior to more general clinical use is of particular importance. ABT-199 at a low nM concentration (<10 nM) was shown to induce apoptosis in CLL cells (Souers et al., 2013). Here, we used ABT-199 at a much higher concentration (1 μM) to test whether it would affect the oscillatory Ca\textsuperscript{2+} signals that normally control physiological enzyme secretion in PACs (Figures 2 and 3; see also Figure 1D, E). Alternations in Ca\textsuperscript{2+} signals towards more global and sustained Ca\textsuperscript{2+} responses could indicate a serious risk of premature enzyme activation in situ in PACs and thus a considerable threat of autodigestion and necrosis of the pancreas, which may develop into acute pancreatitis (Petersen et al., 2011; Gerasimenko et al., 2014).

Single cell Ca\textsuperscript{2+} measurements were performed as described above. In PACs, ACh at nM concentrations triggers Ca\textsuperscript{2+} oscillations, primarily initiated by the IP\textsubscript{3}Rs and further amplified by the ryanodine receptors (RyRs) (Wakui et al., 1990; Cancela, 2001). Potential effects of ABT-199 on ACh-elicited Ca\textsuperscript{2+} release in PACs were assessed in different

![Figure 2](image)

**Figure 2**

ABT-199 does not affect physiological Ca\textsuperscript{2+} responses to ACh in mouse PACs. N, number of independent repeats in the experiments; n, number of independent regions of interest in the experiment (see the text for details). (A) Sample trace (N = 5, n = 40) shows physiological [Ca\textsuperscript{2+}] oscillations in response to 50 nM ACh recorded after 2 h incubation in the extracellular buffer without ABT-199. (B) Sample trace (N = 5, n = 33) shows physiological [Ca\textsuperscript{2+}] oscillations in response to 50 nM ACh recorded after 2 h incubation with 1 μM ABT-199. (C) Responses to ACh are quantitatively analysed by comparing the average [Ca\textsuperscript{2+}] increase above the baseline levels recorded for 600 s post-treatment: control (blue, N = 5, n = 40, 151.8 ± 14.1 a.u.) or in the presence of 1 μM ABT-199 (red, N = 5, n = 33, 136.2 ± 13.9 a.u.). The responses are unaffected by ABT-199. (D) Sample trace (N = 5, n = 33) shows that physiological [Ca\textsuperscript{2+}] oscillations evoked by 50 nM ACh are unaffected by acute application of 1 μM ABT-199. (E) Average traces show [Ca\textsuperscript{2+}] responses in PACs to a supramaximal dose of ACh (10 μM) in the absence of extracellular Ca\textsuperscript{2+}. Cells were incubated for 2 h in the absence (blue trace, N = 6, n = 48) or presence (red trace, N = 7, n = 51) of 1 μM ABT-199. (F) Average traces shown in (E) are quantitatively analysed by comparing the areas under the traces recorded for 200 s post-treatment: 10 μM ACh alone (blue, n = 48, 115.8 ± 6.8 a.u.) and ACh with ABT-199 (red, n = 51, 100.8 ± 5.7 a.u.). Student’s t-test was applied for statistical analysis.
experimental settings (Figure 2). First, the influence of prolonged incubation (2 h) with ABT-199 on 50 nM ACh-evoked oscillatory Ca²⁺ responses was tested and compared to untreated control. No differences were revealed between the control (Figure 2A, blue) and the ABT-199-treated PACs (Figure 2B, red); see also data representing individual areas under the traces (Figure 2C). In addition, acute application of ABT-199 on top of ACh-elicited Ca²⁺ oscillations neither affected the frequencies of the responses nor changed their amplitudes (Figure 2D). Prolonged incubation (2 h) with ABT-199 did not alter the global Ca²⁺ responses to ACh at supramaximal concentration (10 μM) in PACs (Figure 2E, F). CCK, at physiologically relevant concentrations (low pM), induces Ca²⁺ transients in PACs, which are mediated predominantly by the RyRs (Thorn et al., 1994; Cancela, 2001). To test whether ABT-199 alters CCK-elicited responses in PACs (Figure 3), a similar experimental approach as above was adopted. First, the influence of a prolonged incubation (2 h) with ABT-199 on 5 pM CCK-elicited oscillatory Ca²⁺ responses was tested and compared to an untreated control. Importantly, no differences were revealed between the control (Figure 3A, blue) and the ABT-199-treated PACs (Figure 3B, red); see also data representing individual areas under the traces (Figure 3C). Next, when ABT-199 was applied acutely on top of CCK-elicited Ca²⁺ oscillations, neither the frequencies nor the amplitudes of the responses were affected (Figure 3D). Prolonged incubation (2 h) with ABT-199 (Figure 3E) slightly increased the global Ca²⁺ releases elicited by CCK at a supramaximal concentration (10 nM) in PACs (Figure 3E, F). Taken together, these results indicate that ABT-199 does not substantially affect physiological Ca²⁺ responses in PACs.

Inhibitors of Bcl-2 family members affect pathophysiological Ca²⁺ responses in PACs

BH3 mimetics have been developed in order to counteract the Bcl-2-dependent evasion of apoptosis, common in cancers.
Normal cells, such as PACs, are much less dependent on anti-apoptotic Bcl-2 family members than cancer cells. However, even in non-transformed cells, pathophysiological stimulants that trigger cell death could influence the balance between the pro- and anti-apoptotic Bcl-2 proteins and thus may ‘prime these cells for death’. Therefore, pathophysiological stress may reveal additional effects of a BH3 mimetic that do not surface under physiological conditions.

To test whether inhibitors of Bcl-2 proteins would modulate Ca\(^{2+}\) signals in PACs under a pathophysiological stimulus, the cells were incubated (2 h) with different BH3 mimetics (concentrations as in Figure 1) and then treated acutely with TLC-S or menadione. Single-cell Ca\(^{2+}\) measurements in PACs were performed as described above. The bile acid TLC-S, known to induce pathophysiological Ca\(^{2+}\) signals and necrosis in PACs (Gerasimenko et al., 2006), was used here as an initiator of necrotic stress (Figure 4A). An apoptotic stimulus was supplied by menadione, an agent with vitamin K activity, which triggers mitochondrial stress via excessive production of ROS (Figure 4B) (Monks et al., 1992; Gerasimenko et al., 2002). Menadione was also shown to elicit pathophysiological Ca\(^{2+}\) signals in PACs, associated with the induction of apoptosis (Gerasimenko et al., 2002).

Substantial elevations in cytosolic Ca\(^{2+}\) in PACs were induced by 200 μM TLC-S (Figure 4A). These elevations were reduced by the Bcl-2 inhibitor ABT-199 (P < 0.05), whereas A-1155463 (blocker of Bcl-xl) potentiated TLC-S-elicited Ca\(^{2+}\) release (P < 0.05). Interestingly, these two opposite effects cancelled out when ABT-199 and A-1155463 were applied simultaneously. Under the inhibition of a wide range of Bcl-2 family proteins by ABT-737, TLC-S-induced Ca\(^{2+}\) responses were potentiated (P < 0.05).

A similar experimental approach was used to test the effects of BH3 mimetics on 60 μM menadione-elicited Ca\(^{2+}\) elevations in PACs (Figure 4B). ABT-199 alone, despite failing to cause a clear reduction in menadione-driven Ca\(^{2+}\) responses, definitely did not potentiate them. In contrast, A-1155463 (when applied on its own or simultaneously with ABT-199), as well as ABT-737, both increased the pathophysiological Ca\(^{2+}\) elevations induced by menadione (P < 0.05). Taken together, pharmacological inhibition of Bcl-xl via its hydrophobic cleft appears to increase pathophysiological Ca\(^{2+}\) responses, whereas inhibition of Bcl-2 does not have a major impact on Ca\(^{2+}\) homeostasis both in physiology and pathology. Since ABT-199 does not exacerbate pathophysiological Ca\(^{2+}\) signals, it may have a more advantageous safety profile compared to inhibitors that target Bcl-xl.

**BH3 mimetics do not aggravate apoptotic or necrotic cell death in PACs**

As shown above, the new generation of BH3 mimetics may alter TLC-S- or menadione-elicited Ca\(^{2+}\) responses in PACs. Since Ca\(^{2+}\) release is associated with the induction of necrosis and apoptosis, application of Bcl-2 protein inhibitors may modulate PAC death. To determine this, PACs were incubated for 2 h with either TLC-S (200 μM) or menadione (60 μM) in the presence of BH3 mimetics or appropriate vehicles (Figure 5A–C). Annexin V-FITC/PI staining was used to assess the extent of cell death. The number of live (grey), apoptotic (blue), necrotic (red) cells as well as secondary necrosis (pink) was determined and is presented in Figure 5. Importantly, treatment with the selective BH3 mimetics did not induce cell death in PACs, indicating that dependence on Bcl-2/Bcl-xL for survival is rather limited in these cells (Figure 5A). Also, the presence of BH3 mimetics did not significantly alter TLC-S- (Figure 5B) or menadione-induced (Figure 5C) cell death in PACs.

We further scrutinized the effects of ABT-199, given its use in clinical settings. First, a longer (4 h) incubation with ABT-199 (1 μM) did not potentiate the increased cell death that spontaneously occurred in PACs maintained in vitro for longer periods (Figure 5D). Second, we also determined whether the ABT-199 concentration (1 μM) and duration of the treatment (2 h) used in the PAC experiments could kill effectively Bcl-2-dependent cancer cells known to be sensitive to ABT-199 (Anderson et al., 2016; Vervloesem et al., 2017a). For this, two DLBCL cell lines, OCI-LY-1 and Ri-1, and primary CLL lymphocytes obtained from five different patients, were treated with 1 μM of ABT-199 for 2, 4 or 6 h (Figure 5E, F). The number of living cells was determined using Alexa Fluor™ 488 Annexin V/7-AAD or FITC Annexin V/PI staining. In all cell lines and patient samples tested, a 2 h treatment with 1 μM ABT-199 showed extensive cell death that was not dramatically increased by extending the duration of the treatment. This suggests a near maximal effect of ABT-199 at 1 μM in these cancer cells already after 2 h. Taken together, these results indicate that selective Bcl-2 protein family inhibitors neither provoke cell death by themselves nor aggravate cell death induced by pathophysiological stimuli in PACs. For ABT-199, we validated that the concentrations/time periods used were capable of inducing cell death in Bcl-2-dependent cancers.

**Selective inhibition of Bcl-2 affects cytosolic Ca\(^{2+}\) extrusion**

Since Bcl-2 was previously found to regulate cytosolic Ca\(^{2+}\) extrusion in PACs by modulating plasma membrane Ca\(^{2+}\) ATPase (PMCA) activity (Ferdek et al., 2012), we wanted to address whether pharmacological inhibition of Bcl-2 by ABT-199 could affect this process. In order to measure Ca\(^{2+}\) extrusion, a protocol similar to that described before (Ferdek et al., 2012) was used. PACs pretreated for 2 h with 1 μM ABT-199 or incubated for the same amount of time in extracellular buffer (control) were exposed to Tg, a potent SERCA inhibitor, in Ca\(^{2+}\)-free solution (Figure 6A, B). The application of Tg results in the emptying of the ER Ca\(^{2+}\) stores (manifested as the initial response in Figure 6A, B). Increasing extracellular Ca\(^{2+}\) concentration to 10 mM induced Ca\(^{2+}\) influx to the cytosol via store-operated Ca\(^{2+}\) channels, which are opened upon ER Ca\(^{2+}\) depletion. Once a [Ca\(^{2+}\)]\(_{i}\) plateau was established (the second response in Figure 6A, B), extracellular Ca\(^{2+}\) was removed again causing the [Ca\(^{2+}\)]\(_{i}\) to decline towards the baseline levels. Since Ca\(^{2+}\) uptake into the ER is inhibited by Tg, the clearance of [Ca\(^{2+}\)]\(_{i}\) in Ca\(^{2+}\)-free solution reflects Ca\(^{2+}\) extrusion across the plasma membrane, mainly via PMCA. Despite a substantial variability in cytosolic Ca\(^{2+}\) extrusion rates in both control and ABT-199-treated cells, the apparent rate of extrusion was on average slightly faster in the presence of ABT-199 (Figure 6A, B, sample traces). The distribution of the linear fits to the extrusion rates in
ABT-199-treated cells was shifted towards those with faster declines (Figure 6C). This difference is well reflected by a lower $t_{1/2}$ (72.7 ± 4.2 s) for ABT-199-treated PACs compared to control cells (87.7 ± 5.7 s), which translates into a shorter time required for the fluorescence of the Ca$^{2+}$ indicator to decrease by half the difference between the [Ca$^{2+}$] $i$ plateau and the baseline (Figure 6D). Although this effect is relatively minor and also much less prominent to that observed upon the complete loss of Bcl-2 (Ferdek et al., 2012), a potentiation of cytosolic Ca$^{2+}$ extrusion may underlie the modest reduction of pathophysiological Ca$^{2+}$ responses evoked by TLC-S in the presence of ABT-199 (Figure 4A).

Figure 4
ABT-199 does not potentiate pathophysiological Ca$^{2+}$ responses evoked by TLC-S or menadione. $N$, number of independent repeats in the experiments; $n$, number of independent regions of interest in the experiment (see the text for details). (A) Dot chart shows response areas calculated for the first 1000 s of [Ca$^{2+}$] $i$ responses (and corresponding traces below show typical [Ca$^{2+}$] $i$ responses) recorded in mouse PACs to 200 µM TLC-S alone (Ctrl $N = 6$, $n = 78$, 196.8 ± 18.8 a.u.) or in the presence of 1 µM ABT-199 ($N = 6$, $n = 93$, 130.3 ± 10.0 a.u.), 1 µM A-1155463 ($N = 5$, $n = 55$, 264.2 ± 10.4 a.u.), 1 µM ABT-199 together with 1 µM A-1155463 ($N = 5$, $n = 61$, 213.1 ± 10.4 a.u.) or 10 µM ABT-737 ($N = 5$, $n = 65$, 243.0 ± 12.9 a.u.). Cells were incubated for 2 h in the buffer with or without the appropriate inhibitor/s. One-way ANOVA together with the Bonferroni’s post hoc test were used for the statistical analysis; #, significant versus treatment with TLC-S; ¶, significant versus treatment with TLC-S + ABT-199. (B) Dot chart shows response areas calculated for the first 1000 s of [Ca$^{2+}$] $i$ responses (and corresponding traces below show typical [Ca$^{2+}$] $i$ responses) recorded in mouse PACs to 60 µM menadione alone (Ctrl $N = 6$, $n = 45$, 112.0 ± 11.2 a.u.) or in the presence of 1 µM ABT-199 ($N = 5$, $n = 42$, 96.2 ± 11.1 a.u.), 1 µM A-1155463 ($N = 5$, $n = 40$, 159.5 ± 15.7 a.u.), 1 µM ABT-199 together with 1 µM A-1155463 ($N = 5$, $n = 33$, 176.4 ± 16.0 a.u.) or 10 µM ABT-737 ($N = 6$, $n = 56$, 151.9 ± 10.1 a.u.). Cells were incubated for 2 h in the buffer with or without the appropriate inhibitor/s. Scale bars for both: vertical 0.5 F/F0 and horizontal 200 s. Kruskal–Wallis one-way ANOVA (a nonparametric test) was used here for statistical analysis; #, significant versus treatment with menadione; ¶, significant versus treatment with menadione + ABT-199.

ABT-199 is not toxic for pancreatic acinar cells
Discussion

It is very well established that the Bcl-2 family proteins play a role in the regulation of intracellular Ca$^{2+}$ homeostasis (Vervliet et al., 2016). Although primarily associated with the mitochondrial membranes, these proteins also reside in other cell compartments such as the cytosol, the ER and the nuclear envelope (Krajewski et al., 1993). At the ER (the main intracellular Ca$^{2+}$ store), the anti-apoptotic Bcl-2-family members regulate several proteins involved in Ca$^{2+}$ signalling (Vervliet et al., 2016), including the IP$_3$R (Rong et al., 2008, 2009; Ivanova et al., 2014). The binding of Bcl-2 and Bcl-xL to the C-terminal region of IP$_3$R results in sensitization of the receptor and triggers pro-survival Ca$^{2+}$ oscillations (White et al., 2005; Eckenrode et al., 2010). Bcl-2 also interacts with the central regulatory domain of IP$_3$R via its BH4 domain.
the above interactions and indirectly modulate intracellular Ca\textsuperscript{2+} homeostasis.

Inhibition of the anti-apoptotic Bcl-2 members by the early generation BH3 mimetics, BH3I-2\textsuperscript{a} and HA14-1, was associated with global and sustained Ca\textsuperscript{2+} responses induced in normal mouse PACs and in the rat pancreatic cancer cell line AR42J (Gerasimenko et al., 2010). These BH3 mimetic-elicited responses were later shown to be dependent on Bax, but not Bak or Bcl-2 (Ferdek et al., 2017). Moreover, HA14-1 was demonstrated to inhibit SERCA and deplete ER Ca\textsuperscript{2+} stores, causing the ER stress-mediated cell death (Hermanson et al., 2009; Akl et al., 2013).

This study demonstrates that selective inhibition of Bcl-2 by ABT-199 neither triggers substantial intracellular Ca\textsuperscript{2+} release in PACs (Figure 1) nor affects Ca\textsuperscript{2+} responses elicited by endogenous agonists at physiologically relevant concentrations (Figures 2 and 3). Targeted inhibition of Bcl-xL by A-1155463 only had a minor effect on the intracellular Ca\textsuperscript{2+} homeostasis, occasionally inducing infrequent Ca\textsuperscript{2+} transients in PACs (Figure 1C). In contrast, inhibition of more than one Bcl-2 family member via simultaneous application of ABT-199 and A-1155463 (Figure 1B) or by ABT-737 (blocker of Bcl-2, Bcl-xL and Bcl-w; Figure 1A) triggered sporadic intracellular Ca\textsuperscript{2+} rises in PACs or a prolonged Ca\textsuperscript{2+} plateau. This suggests that the toxic effects of BH3 mimetics on Ca\textsuperscript{2+} associated with the inhibition of a wide range of the anti-apoptotic Bcl-2 proteins could be avoided by selectively targeting only one family member, specifically Bcl-2 itself (Figure 1E). Although it was previously shown that ABT-199 does not alter intracellular Ca\textsuperscript{2+} signalling in cell lines, including Bcl-2-dependent DLBCL cancer cell models (Vervooesem et al., 2017b), this study is one of the first few to extend that finding to non-transformed primary cells. Given the toxic effects of early generation BH3 mimetics on PACs, it was particularly timely and relevant to scrutinize the impact of the newly approved drug ABT-199 on physiological and pathophysiological signalling in the exocrine pancreatic system and thus to elucidate potential pancreatexic effects (Figures 1–5).

ABT-199 did not alter Ca\textsuperscript{2+} responses elicited by physiological or supramaximal concentrations of ACh (Figure 2). These responses are primarily initiated by IP\textsubscript{3}R-mediated Ca\textsuperscript{2+} release from the ER and further amplified by RyRs (Wakui et al., 1990; Cancela, 2001). Physiological CCK signalling, mediated by RyRs, was also essentially unaffected by ABT-199 (Figure 3). A minor effect on CCK responses was only present at very high concentrations of the secretagogue. These results are in line with our previous work in cell models where we showed that binding to and regulation of IP\textsubscript{3}R and RyRs by Bcl-2 is independent of its hydrophobic cleft (Vervliet et al., 2015; Ivanova et al., 2016), and thus, it is unlikely to be affected by BH3 mimetics that interact with this site.

Although inhibition of Bcl-xL by A-1155463 or pan-inhibition of Bcl-2/Bcl-xL/Bcl-w by ABT-737 potentiated pathophysiological Ca\textsuperscript{2+} responses induced by TLC-S or menadione, selective inhibition of Bcl-2 by ABT-199 did not (Figure 4). In fact, TLC-S-elicited Ca\textsuperscript{2+} responses were even reduced in the presence of ABT-199 (Figure 4A). This might be due to a modest effect of ABT-199 on cytosolic Ca\textsuperscript{2+} extrusion (Figure 6), which is almost exclusively dependent on PMCA thereby inhibiting excessive pro-apoptotic Ca\textsuperscript{2+} release (Chen et al., 2004; Rong et al., 2009; Monaco et al., 2012). Besides IP\textsubscript{3}Rs, the anti-apoptotic Bcl-2 proteins also regulate intracellular Ca\textsuperscript{2+} handling via RyRs (Vervliet et al., 2014), SERCA (Kuo et al., 1998) and Bax inhibitor-1 (Xu et al., 2008) at the ER, as well as PMCA (Ferdek et al., 2012) and the mitochondrial voltage-dependent anion channel (Arbel and Shoshan-Barmatz, 2010). Therefore, agents that bind to and inhibit the Bcl-2-family members may affect some of
activity in PACs (Petersen, 2003; Ferdek et al., 2012). As shown previously, Bcl-2 has been found to have an inhibitory effect on PMCA in PACs (Ferdek et al., 2012). ABT-199 appears to interfere with this function of Bcl-2, thereby enhancing Ca\(^{2+}\) extrusion by alleviating Bcl-2’s inhibitory effect on PMCA.

The moderate suppression of pathological Ca\(^{2+}\) signals by ABT-199 was reversed by A-1155463, when PACs were pre-incubated with both inhibitors before application of TLC-S, indicating that the effects on Ca\(^{2+}\) associated with Bcl-xL inhibition dominate over those triggered by inhibition of Bcl-2 (Figure 4A). Since A-1155463 interacts with the hydrophobic cleft of Bcl-xL, this site appears to play a role in the regulation of intracellular Ca\(^{2+}\) signalling in response to pathophysiological stimulants. The mechanisms remain unclear, although it may relate to interference by these drugs of Bcl-xL-dependent regulation of Ca\(^{2+}\)-release systems like IP\(_3\)Rs (Yang et al., 2016).

Despite the aforementioned effects on pathophysiological Ca\(^{2+}\) responses induced by TLC-S and menadione (Figure 4), neither of the inhibitors used in the study markedly affected cell death in PACs (Figure 5A, D). These results may suggest that the relatively small effects of ABT-199, A-115563 or ABT-737 on Ca\(^{2+}\) homeostasis in PACs are insufficient to increase the sensitivity of normal cells to cell death inducers. This finding could be particularly relevant to the situation when a BH3 mimetic is used in combination with other chemotherapeutic agents. Such combined therapies are currently undergoing clinical trials (Ferdek and Jakubowska, 2017). It is important to note that with the conditions applied (1 μM ABT-199 for 2 h) ABT-199 was potent at inducing cell death in Bcl-2-dependent cancer cells, including the activated B-cell like lymphoma cancer cell line Ri-1, the germinal centre B-cell-like lymphoma cell line OCI-LY-1 and primary cells derived from CLL patients (Figure 5E, F).

In conclusion, we report that selective inhibition of Bcl-2 by ABT-199, apart from having a modest effect on cytosolic Ca\(^{2+}\) extrusion (Figure 6), does not either dramatically alter intracellular Ca\(^{2+}\) signals on its own (Figure 1) or in response to physiological (Figures 2 and 3) and pathophysiological stimuli in isolated PACs (Figure 4). As a consequence, ABT-199 does not sensitize non-transformed healthy PACs to cell death (Figure 5). Therefore, we conclude that since ABT-199 does not substantially affect intracellular Ca\(^{2+}\) homeostasis or sensitize healthy PACs to inducers of cell death, it should be safe for the pancreas when used in therapy for leukaemia.

Acknowledgements

We would like to thank Dr. Giovanni Monaco for the fruitful discussions and Ms. Joanna Jakubowska for the ANOVA analysis using SPSS Statistics 24 software. This work was supported by the Fonds Wetenschappelijk Onderzoek (Research Foundation-Flanders; FWO) grants: G.0C91.14N, G.0A34.16N and G.0901.18N (to G.B.); a Research Council of the KU Leuven grant: OT/14/101 (to G.B.); a Medical Research Council (MRC) programme grant: MR/J002771/1 (to O.H.P., J.V.G. and O.V.G.); the CHILDREN with CANCER UK grants: 2014/167 and 17/248 (to O.V.G. and J.V.G.); the Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research; AIRC) grants: IG2016 Id.19236 (to D.G.E.), as well as the HOMING/2017-4/31 (to P.E.F.) and HOMING/2017-3/23 (to M.A.J.) project grants, both carried out within the HOMING programme of the Fundacja na rzecz Nauki Polskiej (Foundation for Polish Science; FNP), co-financed by the European Union under the European Regional Development Fund. T.V. is a post-doctoral fellow of the FWO and was a recipient of an FWO-travel grant for long-term visits abroad. G.B., J.V.G. and O.V.G. are part of the Scientific Research Community ‘Calcium Signaling in health, disease & therapy (CaSign)’ supported by the FWO (W0.019.17N). The Faculty of Biochemistry, Biophysics and Biotechnology of the Jagiellonian University in Krakow is a partner of the Leading National Research Center (KNOW) supported by the Polish Ministry of Science and Higher Education.

Author contributions

G.B. conceived the study with further input of M.J., P.F. and T.V.; G.B., T.V. and P.F. coordinated the work. M.J., P.F., M.K., C.M. and T.V. performed the experiments. M.J. and P.F. performed the data analysis and made the figures. The manuscript was drafted by T.V., M.J., G.B. and P.F. All authors were involved in the interpretation of the data and critically revised and approved the manuscript for submission.

Conflict of interest

The authors declare no conflicts of interest.

Declaration of transparency and scientific rigour

This Declaration acknowledges that this paper adheres to the principles for transparent reporting and scientific rigour of preclinical research recommended by funding agencies, publishers and other organisations engaged with supporting research.

References

Adams JM, Cory S (2007). The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26: 1324–1337.
Akl H, VandeCaetsbeek I, Monaco G, Kauskot A, Luyten T, Welkenhuyzen K et al. (2013). HA14-1, but not the BH3 mimetic ABT-737, causes Ca\(^{2+}\) dysregulation in platelets and human cell lines. Haematologica 98: e49–e51.
Akl H, Vervoelsem T, Kiviiluoto S, Bittremieux M, Parys JB, De Smedt H et al. (2014). A dual role for the anti-apoptotic Bcl-2 protein in cancer: mitochondria versus endoplasmic reticulum. Biochim Biophys Acta 1843: 2240–2252.
Alexander SPH, Kelly E, Marrion NV, Peters JA, Facenda E, Harding SD et al. (2017a). The Concise Guide to PHARMACOLOGY 2017/18: Overview. Br J Pharmacol 174: S1–S16.
signals in pancreatic acinar cells are dependent on Bax and can be reduced by Ca$^{2+}$-like peptides. Cell Death Dis 8: e2640.

Gerasimenko JF, Ferdek P, Fischer L, Gukovskaya AS, Pandol SJ (2010). Inhibitors of Bcl-2 protein family deplete ER Ca$^{2+}$ stores in pancreatic acinar cells. Pflugers Arch 460: 891–900.

Gerasimenko JV, Flowerdew SE, Voronina SG, Sukhomlin TK, Tepikin AV, Petersen OH et al. (2006). Bile acids induce Ca$^{2+}$ release from both the endoplasmic reticulum and acidic intracellular calcium stores through activation of inositol trisphosphate receptors and ryanodine receptors. J Biol Chem 281: 40154–40163.

Gerasimenko JV, Gerasimenko OV, Palejwala A, Tepikin AV, Petersen OH, Watson AJ (2002). Menadione-induced apoptosis: roles of cytosolic Ca$^{2+}$ elevations and the mitochondrial permeability transition pore. J Cell Sci 115: 485–497.

Gerasimenko JV, Gerasimenko OV, Petersen OH (2014). The role of Ca$^{2+}$ in the pathophysiology of pancreatitis. J Physiol 592: 269–280.

Gerasimenko JV, Peng S, Tsgorka T, Gerasimenko OV (2018). Ca$^{2+}$-signalling underlying pancreatitis. Cell Calcium 70: 95–101.

Green DR (2016). A BH3 mimic for killing cancer cells. Cell 165: 1560.

Hanahan D, Weinberg RA (2011). Hallmarks of cancer: the next generation. Cell 144: 646–674.

Harding SD, Sharman JL, Faccenda E, Southan C, Pawson AJ, Ireland S et al. (2018). The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucl Acids Res 46: D1091–D1106.

Hermanson D, Addo SN, Bajer AA, Marchant JS, Das SG, SRinivasan B et al. (2009). Dual mechanisms of SHA 14-1 in inducing cell death through endoplasmic reticulum and mitochondria. Mol Pharmacol 76: 667–678.

Ivanova H, Ritaine A, Wagner L, Luyten T, Shapovalov G, Welkunhyzen K et al. (2016). The trans-membrane domain of Bcl-Zalpba, but not its hydrophobic cleft, is a critical determinant for efficient IP$_3$ receptor inhibition. Oncotarget 7: 55704–55720.

Ivanova H, Vervliet T, Missiaen L, Parys JB, De Smedt H, Bultynck G (2014). Inositol 1,4,5-trisphosphate receptor-isoforom diversity in cell death and survival. Biochim Biophys Acta - Mol Cell Res 1843: 2164–2183.

Kearney SL, Dahlberg SE, Levy DE, Voss SD, Sellan SE, Silverman LB (2009). Clinical course and outcome in children with acute lymphoblastic leukemia and aspiraginase-associated pancreatitis. Pediatr Blood Cancer 53: 162–167.

Konopleva M, Contractor R, Tsoo T, Samudio I, Ruvolo PP, Kitada S et al. (2006). Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10: 375–388.

Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W, Reed JC (1993). Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res 53: 4701–4714.

Kuo TH, Kim HR, Zhu L, Yu Y, Lin HM, Tsang W (1998). Modulation of endoplasmic reticulum calcium pump by Bcl-2. Oncogene 17: 1903–1910.

Monaco G, Decrock E, Aki H, Ponsaerts R, Vervliet T, Luyten T et al. (2012). Selective regulation of IP$_3$-receptor-mediated Ca$^{2+}$ signaling and apoptosis by the BH4 domain of Bcl-2 versus Bcl-XL. Cell Death Differ 19: 295–309.
Monks TJ, Hanzlik RP, Cohen GM, Ross D, Graham DG (1992). Quinone chemistry and toxicity. Toxicol Appl Pharmacol 112: 2–16.

Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. (2005). An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677–681.

Peng S, Gerasimenko JV, Tsugorka T, Gryshchenko O, Samarasinghe S, Petersen OH et al. (2016). Calcium and adenosine triphosphate control of cellular pathology: asparaginase-induced pancreatitis elicited via protease-activated receptor 2. Philos Trans R Soc Lond B Biol Sci 371. 20150423.

Peng S, Gerasimenko JV, Tsugorka TM, Gryshchenko O, Samarasinghe S, Petersen OH et al. (2018). Galactose protects against cell damage in mouse models of acute pancreatitis. J Clin Invest 128: 3769–3778.

Petersen OH (2003). Localization and regulation of Ca$^{2+}$ entry and exit pathways in exocrine gland cells. Cell Calcium 33: 337–344.

Petersen OH, Gerasimenko OV, Gerasimenko JV (2011). Pathobiology of acute pancreatitis: focus on intracellular calcium and calmodulin. F1000 Med Rep 3: 15.

Petersen OH, Tepikin AV (2008). Polarized calcium signaling in exocrine gland cells. Annu Rev Physiol 70: 273–299.

Raja RA, Schmiegelow K, Albertsen BK, Prunsild K, Zeller B, Vaitekeviene G et al. (2014). Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol. Br J Haematol 165: 126–133.

Rong YP, Aromolaran AS, Bultynck G, Zhong F, Li X, McColl K et al. (2008). Targeting Bcl-2-IP3 receptor interaction to reverse Bcl-2’s inhibition of apoptotic calcium signals. Mol Cell 31: 255–265.

Rong YP, Bultynck G, Aromolaran AS, Zhong F, Parys JB, De Smedt H et al. (2009). The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding to the regulatory and coupling domain of the IP3 receptor. Proc Natl Acad Sci U S A 106: 14397–14402.

Schoenwaelder SM, Jarman KE, Gardiner EE, Hua M, Qiao J, White MJ et al. (2011). Bcl-xl-inhibitory BH3 mimetics can induce a transient thrombocytopenia that undermines the hemostatic function of platelets. Blood 116: 1663–1674.

Souers AJ, Leveson JD, Boghaert ER, Ackler SL, Catron ND, Chen J et al. (2013). ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19: 202–208.

Tao ZF, Hasvold L, Wang L, Wang X, Petros AM, Park CH et al. (2014). Discovery of a potent and selective BCL-XI inhibitor with in vivo activity. ACS Med Chem Lett 5: 1089–1093.

Thorn P, Gerasimenko O, Petersen OH (1994). Cyclic ADP-ribose regulation of ryanodine receptors involved in agonist evoked cytosolic Ca$^{2+}$ oscillations in pancreatic acinar cells. EMBO J 13: 2038–2043.

Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S et al. (2008). ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68: 3421–3428.

Vervliet T, Decrock E, Molgo J, Sorrentino V, Missiaen L, Leybaert L et al. (2014). Bcl-2 binds to and inhibits ryanodine receptors. J Cell Sci 127: 2782–2792.

Vervliet T, Lemmens I, Welkenhuysen K, Tavernier J, Parys JB, Bultynck G (2015). Regulation of the ryanodine receptor by anti-apoptotic Bcl-2 is independent of its BH3-domain-binding properties. Biochem Biophys Res Commun 463: 174–179.

Vervliet T, Parys JB, Bultynck G (2016). Bcl-2 proteins and calcium signaling: complexity beneath the surface. Oncogene 35: 5079–5092.

Vervliet T, Yule DI, Bultynck G (2018). Carbohydrate loading to combat acute pancreatitis. Trends Biochem Sci 43: 741–744.

Vervoetssem T, Akl H, Toussen T, De Smedt H, Parys JB, Bultynck G (2017a). Reciprocal sensitivity of diffuse large B-cell lymphoma cells to Bcl-2 inhibitors BIRD-2 versus venetoclax. Oncotarget 8: 116566–116571.

Vervoetssem T, Ivanova H, Luyten T, Parys JB, Bultynck G (2017b). The selective Bcl-2 inhibitor venetoclax, a BH3 mimetic, does not dysregulate intracellular Ca$^{2+}$ signaling. Biochim Biophys Acta - Mol Cell Res 1864: 968–976.

Vervoetssem T, Kerkhofs M, La Rovere RM, Sneyers F, Parys JB, Bultynck G (2018). Bcl-2 inhibitors as anti-cancer therapeutics: the impact of and on calcium signaling. Cell Calcium 70: 102–116.

Vogler M, Hamali HA, Sun XM, Bampton ET, Dinsdale D, Snowden RT et al. (2011). BCL2/BCL-XI inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation. Blood 117: 7145–7154.

Wakui M, Osipchuk YV, Petersen OH (1990). Receptor-activated cytoplasmic Ca$^{2+}$ spiking mediated by inositol trisphosphate is due to Ca$^{2+}$-induced Ca$^{2+}$ release. Cell 63: 1025–1032.

Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM et al. (2000). Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci U S A 97: 7124–7129.

White C, Li C, Yang J, Petrenko NB, Madesh M, Thompson CB et al. (2005). The endoplasmic reticulum gateway to apoptosis by Bcl-XL modulation of the InsP3R. Nat Cell Biol 7: 1021–1028.

Xu C, Xu W, Palmer AE, Reed JC (2008). Bcl-1 regulates endoplasmic reticulum Ca$^{2+}$ homeostasis downstream of Bcl-2 family proteins. J Biol Chem 283: 11477–11484.

Yang J, Vais H, Gu W, Foskett JK (2016). Biphasic regulation of InsP3 receptor gating by dual Ca$^{2+}$ release channel BH3-like domains mediates Bcl-xL control of cell viability. Proc Natl Acad Sci U S A 113: E1953–E1962.